[1]. National Institute for Health and Care Excellence (2018) Attention Deficit Hyperactivity Disorder: Diagnosis and Management.
[2]. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders. Washington, DC.
[3]. Centers for Disease Control and Prevention (2013) Mental Health Surveillance AmongChildren — United States, 2005–2011.
[4]. Polanczyk GV, Willcutt EG, Salum GA et al (2014) ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol 43:434–442.
[5]. Clemow DB (2017) Misuse of methylphenidate. Curr Top Behav Neurosci 34:99-124.
[6]. Jensen LS, Pagsberg AK, Dalhoff K (2015) Methylphenidate misuse in adult patients and the impact of therapeutic use. Hum Exp Toxicol 34:460-467.
[7]. Kim MG, Kim J, Kim SC et al (2020) Twitter Analysis of the Nonmedical Use and Side Effects of Methylphenidate: Machine Learning Study. J Med Internet Res 22:e16466.
[8]. Rowland SA, Lesesne CA, Abramowitz AJ (2002) The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev 8:162–170.
[9]. Zito JM, Safer DJ, dos Reis S et al (2000) Trends in the prescribing of psychotropic medications to preschoolers. JAMA 283:1025–1030.
[10]. Challman TD, Lipsky JJ (2000) Methylphenidate: its pharmacology and uses. Mayo Clin Proc 7:711–721.
[11]. Grünblatt E, Bartl J, Marinova Z et al (2013) In vitro study methodologies to investigate genetic aspects and effects of drugs used in attention-deficit hyperactivity disorder. J Neural Transm 120:131–139.
[12]. Gumustas F, Yilmaz I, Sirin DY et al (2017) Chondrocyte proliferation, viability and differentiation is declined following administration of methylphenidate utilized for the treatment of attention-deficit/ hyperactivity disorder. Hum Exp Toxicol 36:981–992.
[13]. Kuczenski R, Segal DS (2001) Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J Pharmacol Exp Ther 296:876–883.
[14]. Schmeichel BE, Zemlan FP, Berridge CW (2013) A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: potential relevance to attention deficit hyperactivity disorder. Neuropharmacology 64:321–328.
[15]. Volkow ND, Wang G, Fowler JS et al (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21:1–5.
[16]. Amara SG, Kuhar MJ (1993) Neurotransmitter transporters: recent progress. Annu Rev Neurosci 16:73–93.
[17]. Martin TA, Smith HR, Luessen DJ et al (2019) Functional brain activity is globally elevated by dopamine D2 receptor knockdown in the ventral tegmental area. Brain Research doi: https://doi.org/10.1016/j.brainres.2019.146552
[18]. Mitelman AS, Buchsbaum MS, Christian BT et al (2020) Positive association between cerebral grey matter metabolism and dopamine D2/D3 receptor availability in healthy and schizophrenia subjects: an 18F-fluorodeoxyglucose and 18F-fallypride positron emission tomography study. World J Biol Psychiatry 21:368-382.
[19]. Comim CM, Gomes KM, Réus GZ et al (2014) Methylphenidate treatment causes oxidative stress and alters energetic metabolism in an animal model of attention-deficit hyperactivity disorder. Acta Neuropsychiatr 26:96–103.
[20]. Fagundes AO, Rezin GT, Zanette F et al (2007) Chronic administration of methylphenidate activates mitochondrial respiratory chain in brain of young rats. Int J Dev Neurosci 25:47–51.
[21]. Réus GZ, Scaini G, Furlanetto CB et al (2013) Methylphenidate treatment leads to abnormalities on krebs cycle enzymes in the brain of young and adult rats. Neurotox Res 24:251–257.
[22]. Scaini G, Fagundes AO, Rezin GT et al (2008) Methylphenidate increases creatine kinase activity in the brain of young and adult rats. Life Sci 83: 795–800.
[23]. Banerjee PS, Aston J, Khundakar AA (2009) Differential regulation of psychostimulant-induced gene expression of brain derived neurotrophic factor and the immediate-early gene Arc in the juvenile and adult brain. Eur J Neurosci 29::465–476.
[24]. Gronier B, Aston J, Liauzun C et al (2010) Age-dependent effects of methylphenidate in the prefrontal cortex: evidence from electrophysiological and Arc gene expression measurements. J. Psychopharmacol Oxf Engl 24:1819–1827.
[25]. Yano M, Steiner H (2007) Methylphenidate and cocaine: the same effects on gene regulation? Trends Pharmacol Sci 28:588–596.
[26]. Schmitz F, Pierozan P, Rodrigues AF et al (2016a) Methylphenidate decreases ATP levels and impairs glutamate uptake and Na+,K+-ATPase activity in juvenile rat hippocampus. Mol Neurobiol 4:7796–7807.
[27]. Hu H, Su L, Xu YQ et al (2010) Behavioral and [F-18] fluorodeoxyglucose micro positron emission tomography imaging study in a rat chronic mild stress model of depression. Neuroscience 169:171–181.
[28]. Bailer UF, Narendran R, Frankle WG et al (2012) Amphetamine induced dopamine release increases anxiety in individuals recovered from anorexia nervosa. Int J Eat Disord 45:263-271.
[29]. Goddard AW, Ball SG, Martinez J et al (2010) Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress Anxiety 27:339-350.
[30]. Kacprzak V, Patel NA, Riley E et al (2017) Dopaminergic control of anxiety in young and aged zebrafish. Pharmacol Biochem Behav 157:1-8.
[31]. Yorgason JT, España RA, Konstantopoulos JK et al (2013) Enduring increases in anxiety-like behavior and rapid nucleus accumbens dopamine signaling in socially isolated rats. Eur J Neurosci 37:1022-1031.
[32]. Baculis BC, Diaz MR, Valenzuela CF (2015) Third trimester-equivalent ethanol exposure increases anxiety-like behavior and glutamatergic transmission in the basolateral amygdala. Pharmacol Biochem Behav 137:78-85.
[33]. Leret ML, Millán JA, Antonio MT (2003) Perinatal exposure to lead and cadmium affects anxiety-like behaviour. Toxicology 186:125-130.
[34]. Matsuda S, Matsuzawa D, Ishii D et al (2012) Effects of perinatal exposure to low dose of bisphenol A on anxiety like behavior and dopamine metabolites in brain. Prog Neuro-Psychopharmacol Biol Psychiatry 39:273-279.
[35]. Zhou R, Wang S, Zhu X (2010) Prenatal ethanol exposure attenuates GABAergic inhibition in basolateral amygdala leading to neuronal hyperexcitability and anxiety-like behavior of adult rat offspring. Neuroscience 170:749-757.
[36]. Liu S, Yu M, Xie X et al (2020) Carbofuran induces increased anxiety-like behaviors in female zebrafish (Danio rerio) through disturbing dopaminergic/norepinephrinergic system. Chemosphere 253:126635 doi: 10.1016/j.chemosphere.2020.126635.
[37]. Bolaños CA, Barrot M, Berton O et al (2003) Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood. Biol Psychiatry 54:1317–1329.
[38]. Gray JD, Punsoni M, Tabori NE et al (2007) Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress. J Neurosci. 27:7196-7207.
[39]. LeBlanc-Duchin D, Taukulis HK (2007) Chronic oral methylphenidate administration to periadolescent rats yields prolonged impairment of memory for objects. Neurobiol Learn Mem. 88:312-320.
[40]. Vendruscolo LF, Izídio GS, Takahashi RN et al (2008) Chronic methylphenidate treatment during adolescence increases anxiety-related behaviors and ethanol drinking in adult spontaneously hypertensive rats. Behav Pharmacol 19:21-27.
[41]. Bruchmuller K, Margraf J, Schneider S (2012) Is ADHD diagnosed in accord with diagnostic criteria? Overdiagnosis and influence of client gender on diagnosis. J Consult Clin Psychol 80:128–138.
[42]. Evans WN, Morrill MS, Parente ST (2010) Measuring inappropriate medical diagnosis and treatment in survey data: the case of ADHD among school-age children. J Health Econ 29:657–673.
[43]. Klein-Schwartz W (2003) Pediatric methylphenidate exposures: 7-year experience of poison centers in the United States. Clin. Pediatr. (Phila.) 42:159–164.
[44]. Simchon-Tenenbaum Y, Weizman A, Rehavi M (2015) Alterations in brain neurotrophic and glial factors following early age chronic methylphenidate and cocaine administration. Behav Brain Res 282:125–132.
[45]. Zhang X, Newport GD, Callicott R et al (2016) MicroPET/CT assessment of FDG uptake in brain after long-term methylphenidate treatment in nonhuman primates. Neurotoxicol Teratol 56:68–74.
[46]. Zhang X, Yon Q, Berridge M et al (2018) Application of molecular imaging technology in neurotoxicology research. J Environ Sci C Environ Carcinog Ecotoxicol Rev 36:113-124.
[47]. Scherer EB, da Cunha MJ, Matté C et al (2010) Methylphenidate affects memory, brain-derived neurotrophic factor immunocontent and brain acetylcholinesterase activity in the rat. Neurobiol Learn Mem 94:247–253.
[48]. Schmitz F, Scherer EB, da Cunha MJ et al (2012a) Chronic methylphenidate administration alters antioxidant defenses and butyrylcholinesterase activity in blood of juvenile rats. Mol Cell Biochem 361:281–28.
[49]. Schmitz F, Scherer EB, Machado FR (2012b) Methylphenidate induces lipid and protein damage in prefrontal cortex, but not in cerebellum, striatum, and hippocampus of juvenile rats. Metab Brain Dis 27:605–612.
[50]. Schmitz F, Pierozan P, Rodrigues AF et al (2015) Chronic treatment with a clinically relevant dose of methylphenidate increases glutamate levels in cerebrospinal fluid and impairs glutamatergic homeostasis in prefrontal cortex of juvenile rats. Mol Neurobiol 53:2384–2396.
[51]. Schmitz F, Pierozan P, Rodrigues AF et al (2016b) Methylphenidate causes behavioral impairments and neuron and astrocyte loss in the hippocampus of juvenile rats. Mol Neurobiol 54:4201–4216.
[52]. Schmitz F, Pierozan P, Biasibetti-Brendler H et al (2018) Methylphenidate disrupts cytoskeletal homeostasis and reduces membrane-associated lipid content in juvenile rat hippocampus. Metab Brain Dis 33:693–704.
[53]. Gerasimov MR, Franceschi M, Volkow ND et al (2000) Comparison between intraperitoneal and oral methylphenidate administration: a microdialysis and locomotor activity study. J Pharmacol Exp Ther 295:51–57.
[54]. Rice D, Barone SJr (2000) Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect 108:511–533.
[55]. Andreazza AC, Frey BN, Valvassori SS et al (2007) DNA damage in rats after treatment with methylphenidate. Prog Neuropsychopharmacol Biol Psychiatry 31:1282–1288.
[56]. Baptista PPA, Saur L, Bagatini PB et al (2015) Antidepressant effects of ketamine are not related to ¹⁸F-FDG metabolism or tyrosine hydroxylase immunoreactivity in the ventral tegmental area of Wistar rats. Neurochem Res 40:1153-1164.
[57]. Zanirati G, Azevedo PN, Venturin GT et al (2018) Depression comorbidity in epileptic rats is related to brain glucose hypometabolism and hypersynchronicity in the metabolic network architecture. Epilepsia 59:923–934.
[58]. Bellaver B, Rocha AS, Souza DG et al (2019) Activated peripheral blood mononuclear cell mediators trigger astrocyte reactivity. Brain Behav Immun 80:879-888.
[59]. Silva RBM, Greggio S, Venturin GT et al (2018) Beneficial effects of the calcium channel blocker CTK 01512-2 in a mouse model of multiple sclerosis. Mol Neurobiol 55:9307-9327.
[60]. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Serie B 57:289-300.
[61]. Rubinov M, Sporns O (2010) Complex network measures of brain connectivity: uses and interpretations. NeuroImage 52:1059–1069.
[62]. Takao K, Miyakawa T (2006) Light/dark transition test for mice. J Vis Exp 13:104.
[63]. Upadhya D, Hattiangady B, Shetty GA et al (2016) Neural stem cell or human induced pluripotent stem cell-derived GABA-ergic progenitor cell grafting in an animal model of chronic temporal lobe epilepsy. Curr Protoc Stem Cell Biol 38:2D.7.1-2D.7.47
[64]. Réus GZ, Scaini G, Titus SE et al (2015) Methylphenidate increases glucose uptake in the brain of young and adult rats. Pharmacol Rep 67:1033–1040.
[65]. Berridge CW, Devilbiss DM, Andrzejewski ME et al (2006) Methylphenidate Preferentially Increases Catecholamine Neurotransmission within the Prefrontal Cortex at Low Doses that Enhance Cognitive Function. Biol Psychiatry 60:1111–1120.
[66]. Brus R, Szkilnik R, Kostrzewa RM et al (1995). Modulation of glucose uptake in rat brain after administration of quinpirole and SKF 38393, two central dopamine receptor agonists. Pharmacol Comm 7:87–91.
[67]. Szkilnik R, Ooewiêcimska J, brus R et al (1999) Modulation of glucose uptake in rat’s brain, heart, liver and kidneys, after administration of quinpirole and 7-OH-DPAT, two central dopamine-D receptor agonists. Pharmacol Comm 10:325–8.
[68]. Nowak P, Swoboda M, Szkilnik R et al (2007) Nitric oxide modulates the amphetamine effect on [3H]glucose uptake in the brain of rats prenatally exposed to lead. Pharmacol Rep 59:601–605.
[69]. Kim YW, Shin JC, An YS (2009) Effects of methylphenidate on cerebral glucose metabolism in patients with impaired consciousness after acquired brain injury. Clin Neuropharmacol 32:335–339.
[70]. Hoover WB, Vertes RP (2007) Anatomical analysis of afferent projections to the medial prefrontal cortex in the rat. Brain Struct Funct 212:149–179.
[71]. Calhoon GG, Tye KM (2015) Resolving the neural circuits of anxiety. Nat Neurosci 18:1394–1404.
[72]. Izquierdo A (2017) Functional heterogeneity within rat orbitofrontal cortex in reward learning and decision making. J Neurosci 37:10529–10540.
[73]. Kuniishi H, Ichisaka S, Matsuda S et al (2017) Chronic inactivation of the orbitofrontal cortex increases anxiety-like behavior and impulsive aggression, but decreases depressionlike behavior in rats. Front Behav Neurosci 10:250.
[74]. Shiba Y, Santangelo AM, Roberts AC (2016) Beyond the medial regions of prefrontal cortex in the regulation of fear and anxiety. Front Syst Neurosci 10:12.
[75]. Kalin NH, Shelton SE, Davidson RJ (2007) Role of the primate orbitofrontal cortex in mediating anxious temperament. Biol Psychiatry 62:1134–1139.
[76]. Wallis JD (2011) Cross-species studies of orbitofrontal cortex and value based decision-making. Nat Neurosci 15:13–19.
[77]. Tenney JR, Rozhkov L, Horn P et al (2014) Cerebral glucose hypometabolism is associated with mitochondrial dysfunction in patients with intractable epilepsy and cortical dysplasia. Epilepsia 55:1415–22.
[78]. Zimmer L (2009) Positron emission tomography neuroimaging for a better understanding of the biology of ADHD. Neuropharmacology 57:601–607.
[79]. Wang D, Li X, Gao K et al (2013) Cardiotrophin-1 (CTF1) ameliorates glucose-uptake defects and improves memory and learning deficits in atransgenic mouse model of Alzheimer’s disease. Pharmacol Biochem Behav 107:48–57.
[80]. Zimmer ER, Parent MJ, Souza DG et al (2017). [18F]FDG PET signal is driven by astroglial glutamate transport. Nat Neurosci. 20:393–395.
[81]. van der Marel K, Bouet V, Meerhoff GF et al (2015) Effects of long-term methylphenidate treatment in adolescent and adult rats on hippocampal shape, functional connectivity and adult neurogenesis. Neuroscience 309:243–258.
[82]. Altarelli I, Leroy F, Monzalvo K et al (2014) Planum temporale asymmetry in developmental dyslexia: Revisiting an old question. Hum Brain Mapp 35:5717–5735.
[83]. Toga AW, Thompson PM (2003) Mapping brain asymmetry. Nat Rev Neurosci 4:37–48
[84]. Wang J, Yang QX, Sun X et al (2015) MRI evaluation of asymmetry of nigrostriatal damage in the early stage of early-onset Parkinson’s disease. Parkinsonism Relat Disord 21:590–596.
[85]. Corballis MC (2009) The evolution and genetics of cerebral asymmetry. Philos Trans R Soc Lond B Biol Sci 364:867–879.
[86]. Onal-Hartmann C, Pauli P, Ocklenburg S et al (2012) The motor side of emotions: investigating the relationship between hemispheres, motor reactions and emotional stimuli. Psychol Res 76:311–316.
[87]. Arning L, Ocklenburg S, Schulz S (2013) PCSK6 VNTR polymorphism is associated with degree of handedness but not direction of handedness. PLoS ONE 8:e67251.
[88]. Habib R, Nyberg L, Tulving E (2003) Hemispheric asymmetries of memory: the HERA model revisited. Trends Cogn Sci 7:241–245.
[89]. Thoma P, Bauser DS, Norra C (2014) Do you see what I feel?--Electrophysiological correlates of emotional face and body perception in schizophrenia. Clin Neurophysiol 125:1152–1163
[90]. Derflinger S, Sorg C, Gaser C et al (2011) Grey-matter atrophy in Alzheimer’s disease is asymmetric but not lateralized. J Alzheimers Dis 25:347–357.
[91]. Ben Amor L (2014) 1H-Magnetic resonance spectroscopy study of stimulant medication effect on brain metabolites in French Canadian children with attention deficit hyperactivity disorder. Neuropsychiatr Dis Treat 10:47-54.
[92]. Britton GB, Bethancourt JA (2009) Characterization of anxiety-related responses in male rats following prolonged exposure to therapeutic doses of oral methylphenidate. Pharmacol Biochem Behav 93:451–459.
[93]. Grupe DW, Nitschke JB (2013) Uncertainty and anticipation in anxiety: an integrated neurobiological and psychological perspective. Nat Rev Neurosci 14:488–501.
[94]. Lacroix L, Spinelli S, Heidbreder CA et al (2000) Differential role of the medial and lateral prefrontal cortices in fear and anxiety. Behav Neurosci 114:1119–1130.
[95]. Zelinski EL, Hong NS, Tyndall AV et al (2010) Prefrontal cortical contributions during discriminative fear conditioning, extinction, and spontaneous recovery in rats. Exp Brain Res 203:285–297.
[96].Golubchik P, Rapaport M, Weizman A (2017) The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder. Int Clin Psychopharmacol. 32:289-293.
[97]. Homsi J, Nelson KA, Sarhill N et al (2001) A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care 18:403-407.
[98]. Kerr CW, Drake J, Milch RA et al (2012) Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 43:68-77.
[99]. Lazarus LW, Moberg PJ, Langsley PR et al (1994) Methylphenidate and nortriptyline in the treatment of poststroke depression: a retrospective comparison. Arch Phys Med Rehabil 75:403-406.
[100]. Hardy SE (2009) Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother 7:34-59.
[101]. Brookshire BR, Jones SR (2012) Chronic methylphenidate administration in mice produces depressive-like behaviors and altered responses to fluoxetine. Synapse 66:844-847.
[102]. Carlezon WAJr, Mague SD, Andersen SL (2003) Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry 54:1330–1337.
[103]. Motaghinejad M, Motevalian M, Ebrahimzadeh A et al (2015a) Reduction of methylphenidate induced anxiety, depression and cognition impairment by various doses of venlafaxine in rat. Int J Prev Med. 6:52
[104]. Motaghinejad M, Montevalian M, Larijani SF (2015b) Protective effects of forced exercise against methylphenidate-induced anxiety, depression and cognition impairment in rat. Adv Biomed Res. 4:134.
[105]. Gonçalves J, Baptista S, Silva AP (2014) Psychostimulants and brain dysfunction: a review of the relevant neurotoxic effects. Neuropharmacology 87:135–149.
[106]. Loureiro-Vieira S, Costa VM, de Lourdes Bastos M et al (2017) Methylphenidate effects in the young brain: friend or foe? Int J Dev Neurosci 60:34–47.
[107]. Kudryashov IE, Onufriev MV, Kudryashova IV et al (2001) Periods of postnatal maturation of hippocampus: synaptic modifications and neuronal disconnection. Dev Brain Res 132:113–120.
[108]. Nyakas C, Buwalda B, Luiten PG (1996) Hypoxia and brain development. Prog Neurobiol 49:1–51.
[109]. Wiley MD, Poveromo LB, Antapasis J et al (2009) Kappa-opioid system regulates the long-lasting behavioral adaptations induced by early-life exposure to methylphenidate. Neuropsychopharmacology 34:1339–1350.
[110]. Adriani W, Leo D, Greco D et al (2006) Methylphenidate administration to adolescent rats determines plastic changes on reward-related behavior and striatal gene expression. Neuropsychopharmacology 31:1946–1956.
[111]. Andersen SL, Arvanitogiannis A, Pliakas AM et al (2002) Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat Neurosci 5:13–14.
[112]. Carlezon WAJr, Konradi C (2004) Understanding the neurobiological consequences of early exposure to psychotropic drugs: linking behavior with molecules. Neuropharmacology 47:47–60.
[113]. Mague SD, Andersen SL, Carlezon WAJr (2005) Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biol Psychiatry 57:120–125.
[114]. Lagace DC, Yee JK, Bolaños CA et al (2006) Juvenile administration of methylphenidate attenuates adult hippocampal neurogenesis. Biol Psychiatry 60:1121–1130.
[115]. Motaghinejad M, Motevalian M, Shabbab B (2016) Effects of chronic treatment with methylphenidate on oxidative stress and inflammation in hippocampus of adult rats. Neurosci Lett 619:106–113.
[116]. Réus GZ, Scaini G, Jeremias GC et al (2014) Brain apoptosis signaling pathways are regulated by methylphenidate in young and adult rats. Brain Res 1583:269–276.
[117]. Sadasivan S, Pond BB, Pani AK (2012) Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS One 7:e33693
[118]. Bauermeister JJ, Shrout PE, Chávez L et al (2007) ADHD and gender: are risks and sequela of ADHD the same for boys and girls? J Child Psychol Psychiatry 48:831–839.
[119]. Park JH, Bang YR, Kim CK (2014) Sex and Age Differences in Psychiatric Disorders among Children and Adolescents: High-Risk Students Study. Psychiatry Investig 11:251-7.
[120]. Ehehardt C, Boucherie Q, Pauly V et al (2017) Methylphenidate: Gender trends in adult and pediatric populations over a 7year period. Therapie 72:635-641.
[121]. Bouziane C, Filatova OG, Schrantee A et al (2019) White Matter by Diffusion MRI Following Methylphenidate Treatment: A Randomized Control Trial in Males with Attention-Deficit/Hyperactivity Disorder. Radiology 293:186-192.
[122]. Efron D, Mulraney M, Sciberras E et al (2020) Patterns of long-term ADHD medication use in Australian children. Arch Dis Child 105:593-597.